Colorectal cancer is the third highest incidence among men and women worldwide. Intravenous chemotherapy is the therapeutic alternative most commonly used in the treatment against of the most types of cancers. However, their effectiveness is limited due to lack of specificity/selectivity of chemotherapeutic agents necessitates that makes necessary the high doses administration, leading severe systemic side effects. Bevacizumab was the first monoclonal antibody approved by the FDA for anticancer therapy, and their effectiveness has been demonstrated in the treatment of several solid tumors types. The colon specific release of bevacizumab, by the oral administration of nanostructured systems, represents a promising strategy to increase its specificity action and, subsequent antitumor activity in colon cancer. The bio/mucoadhesive propertie and specific enzymatic degradability of resistant starch and gellan makes them promising materials for the development of colon specific drug release systems. The bevavizumabe delivery for colon in polymeric nanocarriers systems is a rational strategy to increase the biological interaction with the tumoral tissue. Resistant starch and gellan nanoparticles containing bevacizumab will be prepared by polyelectrolytic complexation and characterized by the association efficiency analysis, size, shape, zeta potential, circular dichroism, rheological and thermal properties (DSC and TG/DTG). Cell permeability will be evaluate in Caco-2 cell monolayers. The performance of the nanoparticles as bevacizumab controlled release systems will be evaluated by the vitro release study, in media with pH values that resembles the GIT different portions, and followed by determination of the drug release mechanisms.
News published in Agência FAPESP Newsletter about the scholarship: